This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DaVita (DVA) Expands Operational Footprint Via New Agreement
by Zacks Equity Research
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval
by Zacks Equity Research
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
DexCom (DXCM) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $121.78 in the latest trading session, marking a -0.43% move from the prior day.
DexCom (DXCM) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.
Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio
by Zacks Equity Research
Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is DexCom (DXCM) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Here is What to Know Beyond Why DexCom, Inc. (DXCM) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DexCom (DXCM) Launches One+ Real-time CGM System in Europe
by Zacks Equity Research
DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.
Curious about DexCom (DXCM) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.
Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, DexCom (DXCM) stood at $121.35, denoting a +0.46% change from the preceding trading day.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $124.25 in the latest trading session, marking a +1.88% move from the prior day.
Intuitive Surgical (ISRG) Seeks FDA Nod for Next-Gen da Vinci 5
by Zacks Equity Research
Intuitive Surgical (ISRG) aims to boost its da Vinci portfolio with the addition of its next-generation da Vinci 5 multiport surgical robot.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
DexCom (DXCM) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
DexCom (DXCM) concluded the recent trading session at $127.12, signifying a -1.68% move from its prior day's close.
If You Invested $1000 in DexCom 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA
by Zacks Equity Research
Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.